PolTREG Spolka Akcyjna
GGPW:PTG20.60
PLN
-0.60
(-2.83%)
ISIN
PLPLTRG00038
Return %
Stock
S&P 500
1Y
-23.70
14.20
3Y
-65.08
81.12
5Y
- -
68.34
Capital Structure
PLN
•
in mil. unless spec.Working Capital
PLN
•
in mil. unless spec.Growth Rates
PLN
•
in mil. unless spec.Quarterly Revenue
PLN
•
in mil. unless spec.Quarterly Earnings Per Share
PLN
•
in mil. unless spec.Quarterly Dividends Per Share
PLN
•
in mil. unless spec.Company Description
- CEO
- Piotr Trzonkowski
- Full Time Employees
- 33
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- ul. Botaniczna 20 Gdansk PM Poland 80-298
- IPO Date
- Nov 23, 2021
- Website
- poltreg.com
- Similar Companies
- Business
- Poltreg S.A. Poltreg S.A. is a clinical-stage biotechnology company that develops T-regulatory cell (TREG) based therapies for autoimmune diseases, including type 1 diabetes and multiple sclerosis; its lead candidate PTG-007, an autologous TREG treatment for early-onset type 1 diabetes, advances to phase 2/3 clinical testing, while the pipeline encompasses polyclonal TREGs, CAR-TREGs, multi-edited allogeneic CAR-TREGs, antigen-specific TREGs, TCR-TREGs, and mRNA immunotherapies targeting conditions such as amyotrophic lateral sclerosis, rheumatoid arthritis, and inflammatory bowel disease. Founded in 2015 as a spin-off from the Medical University of Gdansk with over 17 years of TREG clinical experience in more than 100 patients, the company maintains headquarters and research facilities in Gdansk, Poland, and constructs a state-of-the-art 2100 sqm manufacturing plant featuring 15 production lines capable of 1500 therapies annually to GMP/cGMP standards for its products and contract development and manufacturing organization services. Operations emphasize global markets, particularly Europe and the United States, where it seeks pharmaceutical partnerships for commercialization. In recent developments, Poltreg S.A. established a wholly owned U.S. subsidiary, Immuthera, in Delaware in June 2025 to pursue FDA interactions including a Pre-IND meeting request, enhance U.S. market entry, and advance its platform; formed strategic alliances with Kinexum Services LLC for FDA regulatory strategy, Noble Capital Markets for financial advisory, IQVIA for market analyses and business development, and Antion Biosciences for next-generation allogeneic TREG therapies; and listed on the Warsaw Stock Exchange since 2021 while progressing clinical assets toward milestones.